Rakovina Therapeutics Inc. (RKVTF)
| Market Cap | 6.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.56M |
| Shares Out | n/a |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,749 |
| Average Volume | 15,354 |
| Open | 0.2700 |
| Previous Close | 0.3288 |
| Day's Range | 0.2700 - 0.3278 |
| 52-Week Range | 0.2700 - 100.0000 |
| Beta | -0.15 |
| RSI | 36.45 |
| Earnings Date | Aug 29, 2025 |
About Rakovina Therapeutics
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Varia... [Read more]
News
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapie...
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies...
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm's strategic expansion into the oncology field KT-3283, a dual PARP-HDAC inhibitor, to serve as first development ...
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies...
Rakovina Therapeutics Announces Stock Option Grants
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies ...
Rakovina Therapeutics Announces Warrant Exercise Incentive Program
VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company” or “Rakovina”) a biopharmaceutical company advancing cancer therapies through artif...
Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
Compounds developed through collaboration with Variational AI show targeted activity Compounds developed through collaboration with Variational AI show targeted activity
Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC's 2025 Emerging Biotech Company of the Year Award
Award Recognition underscores the importance of AI-driven drug discovery Award Recognition underscores the importance of AI-driven drug discovery
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend...
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation ...
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing next-generation ...
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer...
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cance...
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated All dollar amounts reflected in Canadian dollars unless otherwise stated
Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation
$3 Million Lead Order from Strategic Investors Supports Bold Transformation $3 Million Lead Order from Strategic Investors Supports Bold Transformation
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer ...
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artif...
Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025
Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies Data highlights novel PARP1 and ATR inhibitors with progress toward next-ge...
Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery
VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial...
Rakovina Therapeutics Unveils Preclinical Data at the AACR - World's Premier Cancer Research Forum
VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial...
Rakovina Therapeutics and Variational AI Strengthen Partnership
Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered Collaborations Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered Collabo...
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response t...
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damag...
Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference
VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligenc...